Baricitinib for Refractory Takayasu Arteritis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

December 23, 2023

Study Completion Date

June 8, 2024

Conditions
Takayasu Arteritis
Interventions
DRUG

Baricitinib 4 MG

The patients received Baricitinib for 48 weeks. The method is to take Baricitinib 4mg every day for a period of 48 weeks. All the patients will be followed up prospectively for 48 weeks.

Trial Locations (1)

Unknown

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Liu Tian

OTHER